Abstract
BackgroundDespite the failure of two randomized controlled trials a number of open-label studies and registries suggested the efficacy of rituximab (RTX) in systemic lupus erythematosus (SLE).ObjectivesThe aim of this observational...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
